horiz (2)horiz (2)horiz (2)horiz (2)
  • Solutions
    • PepsinCheck
    • Reflux Band
    • Dx-pH System
    • Stretta
    • Secca
  • Clinicians
  • Patients
  • Blog
  • Events
  • Clinical Library
  • Login
✕
Restech to Revisit the 47th Annual Symposium: Care of the Professional Voice
May 31, 2018
Stretta Therapy Improves Quality of Life & Reduces PPI Dependency
October 6, 2018

University of Kansas Voice and Swallow Center Director, David Garnett MD, FACS delivers keynote presentation in China: “Hyperacidity and the Irritated Airway”

Journeying from Kansas to Zhengzhou, China to share his expertise on reflux and the airway, Dr. David Garnett delivered his talk, entitled “Hyperacidity and the Irritated Airway.”  This information was welcomed by Chinese otolaryngology key opinion leaders. Brandon Wang, Restech’s Director of Asian Market Development and Chinese native, accompanied Dr. Garnett and provided further introduction of Restech’s new Mederi-RF therapeutic product lines.

Dr. Garnett’s lecture covered a thorough review of the reflux landscape — symptoms, empiric treatment, use and controversy of PPIs, and the often confusing and sometimes contradicting collection of published U.S. clinical data. This set the foundation for a common understanding of the elements and pathophysiology of reflux disease.

Dr. Garnett has been utilizing the Restech pH system for nearly a decade to definitively diagnose suspected reflux patients. He explained his simple, yet effective approach to reflux which he categorizes in four parts:

Assessment: Begin with a proper workup, utilizing the Restech pH probe to objectively measure hyperacidity of the airway. Utilizing an objective baseline establishes a reference for any future assessment, progress, or lack thereof.

Evaluation: When analyzing pH study results, including meal periods in the calculations can provide valuable information on the probable activity or reactivation of enzymes such as pepsin. Although the widely practiced procedure is to exclude meal periods when calculating DeMeester and RYAN scores, contrary to this practice, Dr. Garnett points to evidence published documenting the effects of diet on health, including the possibility of local damage from abnormal pH exposure (e.g. dental literature on the effect of carbonated beverages on dental enamel). Assessing the meal periods and pH levels of the food ingested can add insight to formulating a treatment plan; triggers to reflux or acidic food can be managed differently than gastric reflux.

Based on Garnett’s years of experience with extraesophageal reflux, he believes the question should not only be “does the patient have reflux?” but “does the patient have hyperacidity of the airway?”. In considering the broader picture, this increases validity for altering standard protocol in which meal data is redacted from the pH study analysis.

Area Under the Curve (AUC) theory: The concept of AUC is “Time versus Amount: Is moving your hand quickly through a candle flame equal to holding your hand in or near the flame for a long period of time?”

In the past: Clinicians looked at ALL the acid that occurs below a certain level (5.5), which provided one number for the entire 24 hour period. This method correlated to patient symptoms. The higher the number, the more acid per unit time, the worse patient’s symptoms tended to be.

In the future: Clinicians are beginning to focus on analysis of specific sets of time. For example, what is the AUC (total acid exposure) for just meal periods? For just supine periods? If the number is high for meals, focus on treating just the meals, or encouraging behavioral changes related to food intake. If high exposure occurs only at night, focus on nocturnal control. With this approach, not only do we know if there’s high amount of acid, we also know when it is, so we can tailor the treatment to what the individual patient is experiencing.

Garnett presenting

Targeted Treatment: With detailed pH study information, we can establish the best, most individualized treatment plan. Knowing if acid is even present, how much, and at what time(s) is acid exposure the worst helps determine the most appropriate treatment pathway.

Garnett’s systematic approach to patients with airway irritation symptoms begins with objective data to identify and treat the cause. This eliminates empiric therapy, reduces treatment costs and potential caustic side effects, and expedites the path to healing. This method of analysis enables greater precision for treatment with faster and more complete resolution.

Ms. Liu, CEO of Restech’s commercialization partner in China, stated “Shanxi Divine Technology introduced Dx-pH Measurement system and Stretta/Secca procedures from Restech. We combined the diagnosis and treatment; we are at the forefront of the diagnosis and treatment of reflux disease”.

Restech CEO Debra Krahel commented “Shanxi Divine are perfect partners for Restech’s pH system and Stretta product adoption in China. We are working together to bridge the cultural divide through the common language of medicine. Medicine is truly the platform of humanity and the common denominator for caring and compassion in our world. I am humbled and honored to play a part in sharing these technologies that further the diagnosis and treatment of reflux disease. We are grateful for this opportunity to work and learn from our colleagues in China.”

 

ABOUT RESTECH | MEDERI-RF

Restech | Mederi-RF provides the simplest, most accurate reflux monitoring system on the market. The pH test results assist physicians in developing a personalized, targeted treatment plan for their patients. Our newly acquired Stretta therapeutic device delivers non-ablative radio frequency energy to the lower esophageal sphincter muscle, adding strength and stability to effectively reduce reflux and significantly improve symptoms.

 

PRESS CONTACT

Bree Gorman, VP Marketing
Restech | Mederi-RF
marketing@restech.com
858.673.3700

Share

Related posts

March 3, 2022

Study finds significant correlation between LPR and Allergic Rhinitis


Read more
January 18, 2021

16 Million New Patients Covered for Stretta Therapy


Read more
November 19, 2020

Minimally Invasive Stretta Antireflux Procedure Accessible to Millions more Patients


Read more
Dr. Garnett Presents: Hyperacidity and the Irritated Airway
CONTACT

US: +800.352.1512
Int'l: +1 858.673.3700
Fax: 858.673.3783 contact@restech.com

Contact

Distributor Login
Clinician Login
Representative Login

How we Help

Solutions
PepsinCheck
Reflux Band
Restech
Stretta
Secca

About Us

Company
Contact Us
Job Opportunities
International Distributors
Compliance
Privacy Policy
Terms of Use

Follow Us

Respiratory Technology Corporation 11011 Brooklet Dr, Ste 300 Houston TX 77099 | © 2019 Restech. All Rights Reserved.
    FIND A DOCTOR
      Bree Gorman, VP Marketing

      Bree has been an integral part of Restech from the very beginning. She holds a Masters in Public Health from George Washington University, a BFA from The University of Kansas in Visual Communications, and is a National Board Certified Health & Wellness Coach. Her command of marketing, public health/health delivery systems, and human health behavior change gives her a unique perspective in developing effective marketing strategies for the company.  

      Physicians: Fill out the form below to complete your request to be added to the “Find-A-Doctor” map on restech.com

       


      Thomas Ball, PhD, VP Clinical Affairs

      Thomas previously worked as a polysomnographic technologist in the Virginia Mason system, before  moving into sales with Restech in 2007. After spending 9 years working with distributors across Europe, he was moved into an organizational role at the head office in Houston. In this capacity he works closely with sales and marketing to provide clinical support, manages clinical studies, and provides clinical perspectives on business development. In his spare time Thomas plays rugby for Houston Athletic Rugby Club.

      Jeff Klindworth, VP Business Development

      Jeff has over 30 years of experience in the medical device industry and previously worked in sales at companies such as Encision Inc., Interventional Therapies, LLC, Boston Scientific, and United States Surgical Corporation. He has been working as the VP of Sales for Mederi Therapeutics since 2009 and now brings his extensive expertise to Restech.  Jeff was part of the team that bridged the Mederi asset sale to Restech.  His clinical knowledge of the Stretta and Secca technologies is invaluable.  Jeff has three decades of physician relations experience that he brings to Restech as part of the leadership team.

      Ray Bengermino, VP Sales

      Ray joined Restech in May 2018 as the Vice President for Sales. He has been in the medical device, and specifically in the GERD space for more than 18 years. Starting in sales at Sandhill Scientific pH diagnostics, he moved on to Curon Medical when Stretta and Secca were first introduced to the market. He then worked for Given Imaging when Curon closed operations.  When Stretta was relaunced he joined Mederi as VP of Sales.  Ray was instrumental in keeping Stretta alive and the customer based informed when Mederi ceased operation and assets were purchased by Restech.  He is part of the leadership team directing all product sales for Restech. Ray graduated from Old Dominion University in Norfolk with a BS in Marketing and Business Administration.

      Mark Clark, CPA, CFO

      Mark is a seasoned professional and Certified Public Accountant in Texas who brings a unique blend of creative vision and financial expertise to any leadership team. He worked as a Senior Executive for 15 years on a leadership team which grew a private equity backed cash logistics company performing at negative EBITDA on $100 million revenue into an international industry leader with superior profitability on revenue exceeding $1.5 billion. In addition, he spent 10 years as a Senior Manager at Price Waterhouse delivering results-oriented merger & acquisition, audit and strategic consulting services to middle market clientele including over 40 manufacturing, distribution, service, nonprofit and technology clients. Mark currently serves as a Chief Financial Officer and consulting CFO (seven years) providing in-house and outsourced CFO and transactional services to the middle market.

      Larry Suarez

      Larry is the CTO for Restech and holds a B.S. in Computer Science. He is a software architect specializing in remote patient monitoring, medical sensors, and clinical trial software. Larry holds a patent on massively distributed computing and has worked for a number of major software startup companies including Sybase, Oracle, and Teradata.  Larry was also the co-founder of a startup to deliver advanced clinical pathways to patients using mobile devices and medical sensors. Larry is truly a pioneer and now a veteran in the deployment.

      Jeff Schipper

      Jeff has a breadth of experience with over 25 years in engineering and executive positions within major fortune 100 healthcare companies. He also has proven success in startup medical technology companies. Jeff provides leadership in securing and managing Restech’s patent portfolio. He also built Restech’s compliance platform that established regulatory acceptance in 25+ countries worldwide. Jeff’s scientific support and in-depth understanding of the device industry set the foundation for current and future commercial innovations at Restech.

      Leo Roucher

      With nearly 30 years of working with physician thought leaders developing novel and emerging technologies, Leo has played a key role in the development and evolution of balloon angioplasty and stent technologies that revolutionized the therapy of cardiac disease. His experience was instrumental in the development of the patented platform technology which drives the Restech sensor. Leo provides a vision and passion for effecting change in the diagnosis and management of atypical reflux.

      Deb Krahel

      With over 20 years of executive experience in both the private and public sector, Debra brings a broad understanding of healthcare delivery system. With experience managing products aimed at wide scale disease and population management for 20 million subscribers, Debra has extensive experience in effectively and efficiently developing models of delivery that address specific health issues. Debra has also been involved in the legislative process and served as the elected President of the Independent Physician Association of California. Debra is dedicated to bringing tools to the healthcare market that improve and support the clinical process.